Jyothsna Visweswaraiah

Jyothsna Visweswaraiah has a long and varied work experience. In 2004, they were a Junior Research Fellow at the Indian Institute of Science, where they identified novel drug targets in C. albicans for drug development. From 2006 to 2011, they were a Tutor and Graduate Researcher at Massey University, where they discovered novel regulation of stress/starvation activated translational control pathway by translational elongation factors and developed an immunoassay to detect expression of non-secreted proteins in yeast and bacteria. From 2011 to 2016, they were a Post Doctoral Fellow at the National Institutes of Health, where they identified structural elements of ribosome critical for start codon selection during translation initiation. From 2016 to 2017, they were a Research Fellow at Harvard Medical School, where they led a team that screened natural small molecules that boost NAD levels in mammalian cells and collaborated with cosmetic and nutraceutical companies to develop anti-aging creams and supplements. From 2017 to 2021, they were a Principal Scientist, Senior Scientist, and Scientist at Pandion Therapeutics. In 2021, they became an Advisory Board Member at WEST - Women in the Enterprise of Science and Technology, a Communications and Membership Committee Member at The Antibody Society, and an Associate Director at Flagship Pioneering. In 2022, they became the Director of Drug Creation at Seismic Therapeutic.

Jyothsna Visweswaraiah completed their Doctor of Philosophy (PhD) in Biochemistry from Massey University between 2006 and 2011. Prior to that, they obtained their Master of Science (MSc) in Biotechnology from Bangalore University between 2002 and 2004.